CBLIF and psoriasis: Subsequently, the impact of the FCGR3A-V158F and FCGR2A-H131R polymorphisms on anti-TNF response was assessed in a pilot study with biologic-naive Spanish patients diagnosed with moderate-to-severe psoriasis and treated with ADA, INF or ETN (n = 70) [103].